Stockhub

Helix BioPharma Corp.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

23 August 2022

  • curprev 06:4406:44, 23 August 2022 >Nick 832 bytes +832 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors..."
Retrieved from "https://stockhub.co/research/Helix_BioPharma_Corp."